Evidence map›Paper›PMID 37063899›Full record

ArticleFrontiers in immunology2023

C-type lectin receptor agonists elicit functional IL21-expressing Tfh cells and induce primary B cell responses in neonates.

Maria Vono, Beatris Mastelic-Gavillet, Elodie Mohr, Malin Östensson, Josefine Persson, Thorunn A Olafsdottir, Sylvain Lemeille, David Pejoski, Oliver Hartley, Dennis Christensen and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 5 countries.

Maria VonoCenter for Vaccine Immunology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Beatris Mastelic-GavilletCenter for Vaccine Immunology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Elodie MohrCenter for Vaccine Immunology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Malin ÖstenssonDepartment of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden.
Josefine PerssonDepartment of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden.
Thorunn A OlafsdottirFaculty of Medicine, Biomedical Center, University of Iceland, Reykjavik, Iceland.
Sylvain LemeilleDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
David PejoskiCenter for Vaccine Immunology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Oliver HartleyDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Dennis ChristensenVaccine Adjuvant Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
Peter AndersenVaccine Adjuvant Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
Arnaud M DidierlaurentCenter for Vaccine Immunology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Ali M HarandiDepartment of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden.
Paul-Henri LambertCenter for Vaccine Immunology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Claire-Anne SiegristCenter for Vaccine Immunology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
University of Geneva · CHStatens Serum Institut · DKUniversity of Gothenburg · SEUniversity of British Columbia · CAUniversity of Iceland · IS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: C-type lectin receptor (CLR) agonists emerged as superior inducers of primary B cell responses in early life compared with Toll-like receptor (TLR) agonists, while both types of adjuvants are potent in adults. Methods: Here, we explored the mechanisms accounting for the differences in neonatal adjuvanticity between a CLR-based (CAF Results: On day 7 after immunization, HA/CAF01 increased IL6 and IL21 levels in the draining lymph nodes, while HA/GLA-SE increased IL10. CAF01 induced mixed Th1/Th17 neonatal responses while T cell responses induced by GLA-SE had a more pronounced Th2-profile. Only CAF01 induced T follicular helper (Tfh) cells expressing high levels of IL21 similar to levels induced in adult mice, which is essential for germinal center (GC) formation. Accordingly, only CAF01- induced neonatal Tfh cells activated adoptively transferred hen egg lysozyme (HEL)-specific B cells to form HEL Discussion: Collectively, the data show that CLR-based adjuvants are promising neonatal and infant adjuvants due to their ability to harness Tfh responses in early life.

Indexed as

B-LymphocytesGerminal CenterLectins, C-TypeT Follicular Helper CellsAdjuvants, ImmunologicAnimalsAnimals, NewbornInterleukin-21MiceAdjuvants, ImmunologicInterleukin-21Lectins, C-TypeC-type lectin receptor agonistsinterleukin-21 (IL-21)interleukin-6 (IL-6)neonatal vaccinologyT follicular helper (Tfh)toll-like receptor agonistsvaccine adjuvants

Identifiers

PMID37063899
PMCPMC10102809
OpenAlexW4362468736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.